Nayak L, Standifer N, Dietrich J, Clarke JL, et al. Circulating Immune Cell and Outcome Analysis from the Phase 2 Study of PD-L1 Blockade with Durvalumab for Newly Diagnosed and Recurrent Glioblastoma. Clin Cancer Res 2022 Apr 8. pii: 694327. doi: 10.1158/1078-0432.CCR-21-4064.
PMID: 35395080